Bio-Key International Files S-1 for U.S. IPO, Aiming to Transition from OTC
Bio-Key International Inc. (SEC file no. 0001019034), a biometric identity solutions provider previously traded over-the-counter, filed its Form S-1 with the SEC on October 9, 2026 (756 KB), signaling its intent to list on NASDAQ or NYSE.
51CFO view：Transitioning from OTC to a major U.S. exchange requires the CFO to rebuild SEC-grade financial controls: restating historical GAAP compliance (e.g., revenue recognition, intangible amortization), implementing audit-ready ERP systems, preparing SOX 404(a) testing documentation, and transparently disclosing prior governance gaps in the prospectus—posing a high bar for CFOs without prior U.S. IPO experience.
Bio-Key International Inc. (SEC file no. 0001019034), a biometric identity solutions provider previously traded over-the-counter, filed its Form S-1 with the SEC on October 9, 2026 (756 KB), signaling its intent to list on NASDAQ or NYSE.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →